Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way.